570730 Disclosed is the use of deferiprone, or a physiologically acceptable salt thereof, in the manufacture of a medicament to preferentially reduce or render inactive the toxic iron stores in the subcellular compartments of the brain； preferentially reduce or render inactive the toxic iron stores in the mitochondria for the prevention of mitochondrial iron-induced damage； preferentially reduce or render inactive the toxic iron stores in the mitochondria for the treatment of mitochondrial iron-induced damage or treatment of Friedreich ataxia resulting from mitochondrial iron-induced damage.
